JPS57200316A - Examination of pancreatic exocrine function - Google Patents
Examination of pancreatic exocrine functionInfo
- Publication number
- JPS57200316A JPS57200316A JP56084662A JP8466281A JPS57200316A JP S57200316 A JPS57200316 A JP S57200316A JP 56084662 A JP56084662 A JP 56084662A JP 8466281 A JP8466281 A JP 8466281A JP S57200316 A JPS57200316 A JP S57200316A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pancreatic
- activator
- examination
- exocrine function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012190 activator Substances 0.000 abstract 3
- 102000010911 Enzyme Precursors Human genes 0.000 abstract 2
- 108010062466 Enzyme Precursors Proteins 0.000 abstract 2
- 102000013566 Plasminogen Human genes 0.000 abstract 2
- 108010051456 Plasminogen Proteins 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 230000006870 function Effects 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 229940012957 plasmin Drugs 0.000 abstract 2
- 239000004382 Amylase Substances 0.000 abstract 1
- 102000013142 Amylases Human genes 0.000 abstract 1
- 108010065511 Amylases Proteins 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 206010019670 Hepatic function abnormal Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000016222 Pancreatic disease Diseases 0.000 abstract 1
- 206010062237 Renal impairment Diseases 0.000 abstract 1
- 102100037505 Secretin Human genes 0.000 abstract 1
- 108010086019 Secretin Proteins 0.000 abstract 1
- 108010023197 Streptokinase Proteins 0.000 abstract 1
- 235000019418 amylase Nutrition 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 208000024691 pancreas disease Diseases 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 229960002101 secretin Drugs 0.000 abstract 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 229960005202 streptokinase Drugs 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
PURPOSE: To examine the pancreatic exocrine function accurately and surely, without imposing the patient with burden, by using an activator which converts plasminogen i.e. an inactive proenzyme to active-type plasmin.
CONSTITUTION: An activator (e.g. streptokinase) capable of converting a plasminogen which is an inactive proenzyme to an active-type plasmin, is administered to the patient by intravenous injection or intravenous drip. The blood is collected from the patient, and the amounts of amylase, glucagon, insulin, blood sugar, etc. in the serum are determined. The pancreatic diseases are diagnosed from the state of the pancreatic exocrine function. There is no mecessity of inserting a probe, etc. deep into the body, and the examination can be applied even to the patient of the renal or hepatic function disorder. Combined use of a pancreatic stimulator (e.g. secretin) as an activator further improves the effect of diagnosis without stimulating other organs.
COPYRIGHT: (C)1982,JPO&Japio
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56084662A JPS57200316A (en) | 1981-06-01 | 1981-06-01 | Examination of pancreatic exocrine function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56084662A JPS57200316A (en) | 1981-06-01 | 1981-06-01 | Examination of pancreatic exocrine function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS57200316A true JPS57200316A (en) | 1982-12-08 |
Family
ID=13836928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56084662A Pending JPS57200316A (en) | 1981-06-01 | 1981-06-01 | Examination of pancreatic exocrine function |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57200316A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0626568U (en) * | 1992-08-31 | 1994-04-12 | 進 小林 | Storage for indoor installation |
-
1981
- 1981-06-01 JP JP56084662A patent/JPS57200316A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0626568U (en) * | 1992-08-31 | 1994-04-12 | 進 小林 | Storage for indoor installation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE155025T1 (en) | INTRAVENOUS BLOOD PARAMETER MEASUREMENT SYSTEM | |
| JPS5441191A (en) | Glucose-oxygen sensitive electrode | |
| Towne et al. | Mechanism of hyperalimentation in the suppression of upper gastrointestinal secretions | |
| Denyer et al. | Pure pancreatic juice studies in normal subjects and patients with chronic pancreatitis | |
| Werner et al. | The pancreatic response in man to the injection of highly purified secretin and of pancreozymin | |
| KR840005342A (en) | Intravenous fluid preparation | |
| Linscheer et al. | Transfer of medium chain fatty acids from blood to spinal fluid in patients with cirrhosis | |
| Chey et al. | Diagnosis of diseases of the pancreas and biliary tract: Evaluation of pancreozymin-secretin test | |
| JPS57200316A (en) | Examination of pancreatic exocrine function | |
| Lankisch et al. | Effect of synthetic and natural secretin on the function of the exocrine pancreas in man | |
| Schaffalitzky de Muckadell et al. | Physiological Significance of Secretin in the Pancreatic Bicarbonate Secretion: II. Pancreatic Bicarbonate Response to a Physiological Increase in Plasma Secretin Concentration | |
| Williams | Pertechnetate and the stomach—a continuing controversy | |
| AU2003221468A1 (en) | Needle insertion sensor | |
| Ensminger et al. | Hepatic Arterial BCNU: A Pilot Clinical-Pharmacologic Study in Patients | |
| Groisser et al. | Absorption of radioactive sodium from the intestinal tract of man. I. Effect of intestinal motility. II. Effect of an organomercurial | |
| Thjodleifsson et al. | Effect of metiamide on the response to secretin and cholecystokinin in man. | |
| Bridgwater et al. | Pancreozymin-Cholecystokinin Injected by Portal and Systemic Routes. | |
| Kokot et al. | Hepatic inactivation of renin in man | |
| Hildebrandt et al. | Absorption of subcutaneously infused insulin: influence of the basal rate pulse interval | |
| De Muckadell et al. | Plasma secretin concentration and pancreatic exocrine secretion after intravenous secretin or intraduodenal HC1 in anaesthetized pigs | |
| ES8503202A1 (en) | PERFECTED PERFUSION SYSTEM | |
| Jones | Hyaluronidase activity in the skin, rheumatic disease, and salicylates | |
| RU2067864C1 (en) | Method of pancreatic gland external secretion stimulation | |
| Saito et al. | Excretion in bile and clinical study of T-1220 (piperacillin) in biliary tract diseases (author's transl) | |
| Lumbers et al. | Tachyphylaxis to angiotensin in man |